文献速递艾滋病与性传播感染病毒性肝炎

基于索磷布韦的丙型肝炎治疗对接受富马酸替诺福韦二吡呋酯的HIV/HCV合并感染者替诺福韦药代动力学的影响

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

在HIV合并急性HCV感染者中,队列1接受索磷布韦联合利巴韦林治疗12周,队列2接受来迪派韦/索磷布韦治疗8周,比较治疗前后替诺福韦血浆浓度及细胞内替诺福韦二磷酸浓度。结果显示干血斑和PBMC中替诺福韦二磷酸显著升高,队列2血浆替诺福韦也升高,但肌酐清除率仅小幅下降6%-7%。

要点

  • 队列1索磷布韦+利巴韦林12周后,干血斑替诺福韦二磷酸较基线升高4.3倍(95%CI 2.46-7.67;P=0.0001)。
  • 队列2来迪派韦/索磷布韦8周后,干血斑替诺福韦二磷酸较基线升高17.8倍(95%CI 12.77-24.86;P<0.0001)。
  • 两队列治疗前后肌酐清除率仅下降6%-7%,但细胞内替诺福韦二磷酸升高机制和临床意义需进一步研究。

核心结论

  • 基于索磷布韦的HCV治疗与富马酸替诺福韦二吡呋酯在细胞水平存在意料之外的药物相互作用,需进一步研究其机制和临床意义。

研究设计与样本

  • HIV合并急性HCV感染者来自艾滋病临床试验组研究5327,队列1接受索磷布韦+利巴韦林治疗12周,队列2接受来迪派韦/索磷布韦治疗8周。
  • 分析仅纳入服用富马酸替诺福韦二吡呋酯的参与者,队列1有15名男性完成,队列2有22名男性完成。
  • 采用经验证的LC/MS-MS测定血浆替诺福韦、干血斑替诺福韦二磷酸和PBMC替诺福韦二磷酸,在HCV治疗前及研究期间纵向测量。

主要发现

  • 队列1治疗12周后,干血斑替诺福韦二磷酸较研究入组时升高4.3倍(95%CI几何均值比2.46-7.67;P=0.0001),PBMC替诺福韦二磷酸升高2.3倍(95%CI 1.09-4.92;P=0.03),血浆替诺福韦不变。
  • 队列2治疗8周后,干血斑替诺福韦二磷酸较研究入组时升高17.8倍(95%CI 12.77-24.86;P<0.0001),血浆替诺福韦升高2.1倍(95%CI 1.44-2.91;P=0.0005)。
  • 两队列从研究入组至治疗结束时肌酐清除率仅下降6%-7%。

局限性

  • 需要额外研究来确定该相互作用的机制和临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The nucleotide analogues tenofovir and sofosbuvir are considered to have low potential for drug interactions. OBJECTIVES: To determine the effect of sofosbuvir-based HCV treatment on plasma concentrations of tenofovir and cellular concentrations of tenofovir diphosphate. METHODS: HIV-infected participants with acute HCV were treated for 12 weeks with sofosbuvir + ribavirin in Cohort 1 or 8 weeks with ledipasvir/sofosbuvir in Cohort 2 of AIDS Clinical Trials Group study 5327. Only participants taking tenofovir disoproxil fumarate were included in this analysis. Tenofovir in plasma, tenofovir diphosphate in dried blood spots and tenofovir diphosphate in PBMCs were measured pre-HCV therapy and longitudinally during the study using validated LC/MS-MS. RESULTS: Fifteen and 22 men completed Cohorts 1 and 2, respectively. In Cohort 1, tenofovir diphosphate was 4.3-fold higher (95% CI geometric mean ratio 2.46-7.67; P = 0.0001) in dried blood spots and 2.3-fold higher (95% CI 1.09-4.92; P = 0.03) in PBMCs following 12 weeks of sofosbuvir + ribavirin versus study entry. Tenofovir in the plasma was unchanged. In Cohort 2, tenofovir diphosphate was 17.8-fold higher (95% CI 12.77-24.86; P < 0.0001) in dried blood spots after 8 weeks of ledipasvir/sofosbuvir versus study entry. Tenofovir plasma concentrations were 2.1-fold higher (95% CI 1.44-2.91; P = 0.0005). Despite the increase in cellular tenofovir diphosphate concentrations, only a small decline in CLCR (6%-7%) was observed in both cohorts between study entry and end of treatment. CONCLUSIONS: These data indicate an unexpected drug interaction with tenofovir disoproxil fumarate and sofosbuvir at the cellular level. Additional studies are needed to determine the mechanism and clinical significance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. MacBrayne CE, Marks KM, Fierer DS, et al. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother. 2018. PMID: 29746648. doi:10.1093/jac/dky146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。